Reach further, in an Open Access Journal Endocrinology, Diabetes & Metabolism Case Reports

ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P74 

Delayed puberty and bone turnover biochemical markers

Marian Bistriceanu1, Iulia Bistriceanu2, Magda Elvira Preda2, Simona Bondari1, Aurora Covei2 & Liliana Putinelu3

Author affiliations

Background: Delayed puberty means the absence of secondary sexual characters until the age of 16 or the lack of puberty development until the limit of +2DS regarding the age when the puberty normally begins at considered population. Considering the major ethiological factor implied in delayed puberty, three mechanisms can be distinguished: hypothalamic, hypophyseal and gonadal. Osteoporosis depends mainly on the deficiency of one or of all sexual hormones, arised during the ontogenesis process.

Methods: We enrolled 26 cases of delayed puberty, aged 12–35, of which 14 cases (53.85%) of hypergonadotropic hypogonadism (female Turner syndrome – 10 cases; Klinefelter – four cases) and 12 cases (46.15%) of hypogonadotropic hypogonadism (hypophyseal dwarfism with sexual infantilism – three cases; functional adipose-genital syndrome – seven cases; tumor-like hypophyseal insufficiency – two cases). Plasmatic level of the two markers of bone turnover (osteocalcine and CrossLap) was evaluated by ELISA method. Dual absorption with X-rays assesed bone mineral density.

Results: DEXA identified, 10 cases (38.46%) of osteoporosis, where the osteocalcine values (29.4–112.96 ng/ml) and CrossLap (0.197–1.768 ng/ml) were comparable with those of women in postmenopausal period, six cases (23.08%) of osteopenia, and 10 cases (38.46%) of T score value and biochemical markers in normal range.

Conclusions: Our study suggests two major objectives of therapy for existent osteoporosis/osteopenia at delayed puberty pacients: precocious diagnosis of gonadal insufficiency, in to apply some prophylaxis measures for bone modifications beginning from pre-puberty, thus insuring the stabilization or increasing bone mass corresponding to sex and age; therapy associates estro-progestative/ androgenic substitution and antiresorbtion or proformation medication.

This Issue/Conference

Article tools

My recently viewed abstracts

My recent searches